Patent intelligence · US
US 11291663
Methods of treating cancer with farnesyltransferase inhibitors
Methods of treating cancer with farnesyltransferase inhibitors
Patent details — US 11291663
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 5, 2022
- Expiration
- Mar 31, 2042
- Applicant
- Kura Oncology, Inc.
- Claims
- 21
- CPC classes
- A61K, A61K31/4704, A61K31/4709, A61P
Quick answer
US 11291663 (Methods of treating cancer with farnesyltransferase inhibitors) is held by Kura Oncology, Inc.. Status: granted. Granted Apr 5, 2022. Expires Mar 31, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Kura Oncology, Inc.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/4704, A61K31/4709, A61P, A61P35/02
More from Kura Oncology, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12410184
Crystalline forms of a menin inhibitor
granted -
US 12377026
Dental adhesive material kit
granted -
US 12358210
Resin composition for stereolithography
granted -
US 12344691
Resin composition for stereolithography
granted -
US 12214061
Adhesive composition for dental use
granted -
US 12208148
Dental restorative curable composition
granted -
US 12145888
Zirconia molded body and pre-sintered body capable of being sintered in short time
granted -
US 12138325
Dental composition
granted
Frequently asked questions
What is US patent 11291663?
US 11291663 (Methods of treating cancer with farnesyltransferase inhibitors) is held by Kura Oncology, Inc.. Status: granted. Granted Apr 5, 2022. Expires Mar 31, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11291663?
Kura Oncology, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 132 pharmaceutical patents for this assignee.
When does US 11291663 expire?
Our index shows an expiration date of Mar 31, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.